Research

Eisai currently works across Europe in the areas of Alzheimer’s disease, gastro-intestinal disorders, epilepsy, cervical dystonia and severe, chronic pain, and is moving into neurology, cancer and critical care with its development portfolio.

Understanding the future information for investors